

SANOFI-AVENTIS  
Form 6-K  
July 19, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2010

Commission File Number: 001-31368

**SANOFI-AVENTIS**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Edgar Filing: SANOFI-AVENTIS - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

## Edgar Filing: SANOFI-AVENTIS - Form 6-K

In July 2010, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 to 99.10 which are incorporated herein by reference.

### Exhibit List

| <b>Exhibit</b> |   |
|----------------|---|
| <b>No.</b>     | <b>Description</b>  |
| Exhibit 99.1   | Press release dated June 4, 2010: Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology                                     |
| Exhibit 99.2   | Press release dated June 5, 2010: Teriflunomide in adjunct to interferon beta significantly improved outcomes of Multiple Sclerosis patients                                  |
| Exhibit 99.3   | Press release dated June 8, 2010: Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases                           |
| Exhibit 99.4   | Press release dated June 17, 2010: Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review  |
| Exhibit 99.5   | Press release dated June 22, 2010 : Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics  |
| Exhibit 99.6   | Press release dated June 25, 2010: Sanofi-aventis and Metabolex enter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II Diabetes |
| Exhibit 99.7   | Press release dated June 25, 2010: Improved Outcomes for Patients Treated with Lantus® and Apidra® Regimen Compared with Sliding Scale Insulin                                |
| Exhibit 99.8   | Press release dated June 26, 2010: Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin                     |
| Exhibit 99.9   | Press release dated June 30, 2010: Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company  |
| Exhibit 99.10  | Press release dated July 1 <sup>st</sup> , 2010: Sanofi-aventis and JDRF Form Partnership to Improve Therapies, Work Toward Cure for Type 1 Diabetes                          |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 19, 2010

SANOFI-AVENTIS

By */s/ JOHN FELITTI*  
Name: **John Felitti**  
Title: **Associate Vice President,  
Corporate Law, Financial & Securities Law**

**Exhibit Index**

| <b>Exhibit</b> |   |
|----------------|---|
| <b>No.</b>     | <b>Description</b>  |
| Exhibit 99.1   | Press release dated June 4, 2010: Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology                                     |
| Exhibit 99.2   | Press release dated June 5, 2010: Teriflunomide in adjunct to interferon beta significantly improved outcomes of Multiple Sclerosis patients                                  |
| Exhibit 99.3   | Press release dated June 8, 2010: Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases                           |
| Exhibit 99.4   | Press release dated June 17, 2010: Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review  |
| Exhibit 99.5   | Press release dated June 22, 2010 : Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics  |
| Exhibit 99.6   | Press release dated June 25, 2010: Sanofi-aventis and Metabolex enter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II Diabetes |
| Exhibit 99.7   | Press release dated June 25, 2010: Improved Outcomes for Patients Treated with Lantus® and Apidra® Regimen Compared with Sliding Scale Insulin                                |
| Exhibit 99.8   | Press release dated June 26, 2010: Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin                     |
| Exhibit 99.9   | Press release dated June 30, 2010: Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company  |
| Exhibit 99.10  | Press release dated July 1 <sup>st</sup> , 2010: Sanofi-aventis and JDRF Form Partnership to Improve Therapies, Work Toward Cure for Type 1 Diabetes                          |